ArticleCardiovascular drugs and therapy2026
Therapeutic Potential of Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicles in Atherosclerotic Stenosis and Endothelial Dysfunction.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ANRIL in Cardiovascular Diseases: Expression, Mechanism and Therapeutic Implications.Cardiovascular drugs and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundAtherosclerotic stenosis is a progressive vascular disease characterized by vascular narrowing. Bone marrow mesenchymal stem cell-derived extracellular vesicles (BMSC-EVs) have been reported to alleviate endothelial cell dysfunction. AIM AND
methodsHere, we investigated the therapeutic potential of BMSC-EVs in a rabbit model of diabetic atherosclerotic stenosis and in a high-glucose-induced human umbilical vein endothelial cell (HUVEC) injury model.
resultsHistological analysis confirmed the successful establishment of the animal model. Treatment with BMSC-EVs effectively reduced intimal thickening and lipid accumulation, attenuated collagen deposition, reduced smooth muscle cell proliferation, and alleviated macrophage infiltration. Additionally, BMSC-EVs treatment decreased the expression of pro-inflammatory cytokines and improved serum lipid profiles. The HUVEC injury model recapitulates the key features of endothelial dysfunction, including decreased cell viability, increased apoptosis, oxidative stress, and proinflammatory cytokine expression. Treatment with BMSC-EVs alleviated these effects by enhancing cell viability, suppressing apoptosis, reducing oxidative stress, and lowering pro-inflammatory cytokine expression. Mechanistically, BMSC-EVs inhibited the expression of apoptotic markers, including Bax and Cleaved Caspase 3, while enhancing the phosphorylation of heat shock protein 27 (HSP27), a cytoprotective molecule, and its upstream activator P38. HSP27 knockdown reversed the anti-apoptotic and antioxidant effects of BMSC-EVs, highlighting the crucial role of HSP27 in mediating these effects.
conclusionOur findings suggest that BMSC-EVs hold promise as a therapeutic intervention for vascular endothelial injury associated with atherosclerosis and diabetes mellitus. Targeting HSP27 may be a potential strategy to enhance the therapeutic efficacy of BMSC-EVs in endothelial dysfunction.
Indexed as
Identifiers
41313541What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.